Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: A decision analysis

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 2, Issue 4, 2005, Pages 411-418

  Shermock, Kenneth M ^a   Gildea, Thomas R ^b   Singer, Mendel ^c   Stoller, James K ^b,d  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Alpha 1 antitrypsin deficiency; Costs and cost analysis; Genetic screening

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BIRTH; CIGARETTE SMOKING; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; HUMAN; MASS SCREENING; MONTE CARLO METHOD; NEWBORN; NEWBORN SCREENING; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; SENSITIVITY ANALYSIS; STATISTICAL MODEL;

ALPHA 1-ANTITRYPSIN DEFICIENCY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; MARKOV CHAINS; MASS SCREENING; MONTE CARLO METHOD; PHENOTYPE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 33745076743     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550500346469     Document Type: Article

References (33)

1. Khoury MJ, McCabe LL, McCabe ERB. Population screening in the age of genomic medicine. N Engl J Med 2003; 348:50-58.
2. Farrell PM, Kosorok MR, Laxova A, Shen G, Kosaik RE, Bruns WT, Splaingard M, Mischler EH. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 1997; 337:963-969.
3. Sveger T, Thelin T. Four-year-old children with alpha 1-antitrypsin deficiency. Clinical follow-up and parental attitudes towards neonatal screening. Acta Paediatr Scand 1981; 70:171-177.
4. Clayton EW. Ethical, legal, and social implications of genomic medicine. N Engl J Med 2003; 349:562-569.
5. McCabe ER. Clinical genetics: compassion, access, science, and advocacy. Genet Med 2001; 3:426-429.
6. O'Brien ML, Buist NR, Murphey WH. Neonatal screening for alphal-antitrypsin deficiency. J Pediatr 1978; 92:1006-1010.
7. Sveger T, Mazodier P. Alpha 1-antitrypsin screening of 18-year-old men. Thorax 1979; 34:397-400.
8. Piitulainen E, Sveger T. Effect of environmental and clinical factors on lung function and respiratory symptoms in adolescents with alphal-antitrypsin deficiency. Acta Paediatr 1998; 87:1120-1124.
9. Sveger T, Thelin T, McNeil TF. Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition. Acta Paediatr 1997; 86:37-40.
10. Thelin T, McNeil TF, Aspegren-Jansson E, Sveger T. Psychological consequences of neonatal screening for alpha 1-antitrypsin deficiency. Parental reactions to the first news of their infants' deficiency. Acta Paediatr Scand 1985; 74:787-793.
11. Fost N, Farrell PM. A prospective randomized trial of early diagnosis and treatment of cystic fibrosis: a unique ethical dilemma. Clin Res 1989; 37:495-500.
12. 1 decline in individuals with severe deficiency of alpha 1-antitrypsin. Am J Respir Crit Care Med 1998; 158:49-59.
13. Seersholm N, Dirksen A, Kok-Jensen A. Airways obstruction and two year survival in patients with severe alpha 1-antitrypsin deficiency. Eur Respir J 1994; 7:1985-1987.
14. Stoller JK. Augmentation therapy for severe alpha 1-antitrypsin deficiency: is the jury still out on a trial? Thorax 1998; 53:1007-1009.
15. Wall M, Moe E, Eisenberg J, Powers M, Buist N, Buist AS. Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency. J Pediatr 1990; 116:248-251.
16. Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003; 167:1387-1392.
17. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S77-S121.
18. McElvaney NG, Stoller JK, Buist AS, Prakash UB, Brantly ML, Schluchter MD, Crystal RG. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111:394-403.
19. The Alpha 1-Antitrypsin Deficiency Registry Study Group. A registry of patients with severe deficiency of alpha 1-antitrypsin. Design and methods. Chest 1994; 106:1223-1232.
20. CDC. Annual smoking-attributable mortality, years of pitential life lost, and economic costs-United States, 1995-1999. MMWR 2002; 51:300-303.
21. Brantly M. Personal communication, 2003.
22. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000; 118:1278-1285.
23. Ramsey SD, Patrick DL, Albert RK, Lewis S, Albert RK, Raghu G. The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. Chest 1995; 108:1594-1601.
24. Sharples LD, Taylor GJ, Karnon J, Caine N, Buxton M, McNeil K, Wallwork J. A model for analyzing the cost of the main clinical events after lung transplantation. J Heart Lung Transplant 2001; 20:474-482.
25. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 1995; 7:490-502.
26. Siegel JES, Weinstein MCP, Russell LBP, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA October 23/30 1996; 276:1339-1341.
27. Gold MR, Siegel JE, Russell LB. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
28. Silverman EK, Miletich JP, Pierce JA, Sherman LA, Endicott SK, Broze GJ Jr., Campbell EJ. Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis 1989; 140:961-966
29. Anderson R, DeTurk P. United States Life Tables, 1999. National Vital Statistics Reports 2002; 50.
30. Sveger T, Thelin T, McNeil TF. Neonatal alpha 1-antitrypsin screening: parents' views and reactions 20 years after the identification of the deficiency state. Acta Paediatr 1999; 88:315-318.
31. Helton JL, Harmon RJ, Robinson N, Accurso FJ. Parental attitudes toward newborn screening for cystic fibrosis. Pediatr Pulmonol Suppl 1991; 7:23-28.
32. McNeil TF, Harty B, Thelin T, Aspegren-Jansson, Sveger T. Identifying children at high somatic risk: long-term effects on mother-child interaction. Acta Psychiatr Scand 1986; 74:555-562.
33. Brantly ML, Mishra VS, Viranovskaya N, et al. Statewide targeted screening and detection of alpha-1 antitrypsin deficient individuals. Am J Respir Crit Care Med 2003; 167:A222 [abstract].